Original research articleCycle control, quality of life and acne with two low-dose oral contraceptives containing 20 μg ethinylestradiol
Introduction
Since their introduction in the 1960s, oral contraceptives (OCs) have undergone significant changes, from reduction of the estrogen content to modification of the progestogen component. These changes have all been implemented to reduce unwanted side effects associated with the high dosages of the earlier pills [1], [2], [3], [4], [5], [6], [7], [8], [9]. In the 1980s, the estrogen dose was reduced to as little as 30 μg per pill, which still provided good cycle control with little spotting or breakthrough bleeding and high efficacy. Recently, several 20 μg ethinylestradiol-containing OCs have been developed, which also claim good cycle control and efficacy comparable to other higher-dosed pills due to the high selectivity of modern progestogens [10], allowing reduction of ethinylestradiol dose without loss of efficacy and cycle control. In the current trend for women to use less hormones, these low-dose pills suit their needs. Poor cycle control and low tolerability can be a reason for low pill compliance. Ethinylestradiol is the main component of the combined OC, regulating cycle control and also inducing (subjective) side effects [11], [12]. These symptoms can also affect a woman's self-perception and her quality of life. Data on quality of life in young healthy pill users is very limited. This study was performed to compare two different low-dose combined OCs containing 20 μg ethinylestradiol and either desogestrel or levonorgestrel on their effect on cycle control and quality of life. It is thought that desogestrel, having a significantly stronger affinity for the progestogen receptor and a lower affinity for the androgen receptor than levonorgestrel [10], would have a better effect on cycle control, quality of life and acne.
Section snippets
Methods
This was an open-label, randomized, controlled, multicenter clinical trial performed in 50 general practitioner and gynecological practices in Germany and the Netherlands. Eligible participants were women between 18 and 45 years of age, in good physical and mental condition, sexually active, with a body mass index between 18 and 29 kg/m2. Women could not participate if their menstrual cycle was shorter than 24 days or longer than 35 days, if they were older than 35 years and smoking, if they
Demographics
A total of 1027 women were enrolled and randomized to treatment (517 women received 20EE/DSG, 510 received 20EE/LNG). Of these, 404 (78.1%) and 384 (75.3%) completed the trial, respectively. Mean age was 28.2 years (range 17–45). There was no clinically significant change in blood pressure or body weight. In both groups there were more pill switchers than pill starters. Pill compliance was high in both groups (>98%) and mean follow-up time was a little over five cycles. More demographic details
Discussion and conclusion
To our knowledge, this is the first randomized clinical trial in which two low-dose combined OCs containing 20 μg ethinylestradiol were compared.
A better cycle control was achieved with 20EE/DSG than with 20EE/LNG. Irregular bleeding and spotting occurred statistically significantly more in the 20EE/LNG group, the difference being caused rather by spotting than by irregular bleeding. The results from this study support earlier findings that 20EE/DSG provides good cycle control [15]. As stated
Acknowledgments
This study was kindly sponsored by NV Organon, Oss, the Netherlands. The authors wish to thank the following persons for their contribution to this study: Germany: Sylvia Zuckschwerdt, Ulrich-J. Koch, Viola Glanz, Barbara Börner, Sylvia Gramatte, Berlin; Bianca Opelka, Oranienburg; Ralf Bensch, Wittenburg; Roswitha Hellmich, Ursula Schlenk, Dresden; Victoria Piesold, Erfurt; Laslo Koos, Barbara Doll, Kurt Stahmer, Hamburg; Robert Hoene, Ahrensburg; Gabriele Simko-Leonhard, Wiesbaden; Sybille
References (19)
- et al.
Contraceptives and cerebral thrombosisa five-year national case-control study
Contraception
(2002) Coagulation and anticoagulation effects of contraceptive steroids
Am J Obstet Gynecol
(1994)- et al.
Cervical cancer and use of hormonal contraceptivesa systematic review
Lancet
(2003) - et al.
Selectivity in progesterone and androgen receptor binding of progestagens used in oral contraceptives
Contraception
(1988) Clinical experience and pharmacological effects of an oral contraceptive containing 20 micrograms oestrogen
Contraception
(1992)- et al.
Low dose oral contraceptives and quality of life
Contraception
(1999) - et al.
A prospective study of the effects of oral contraceptives on sexuality and well-being and their relationship to discontinuation
Contraception
(2001) - et al.
Hormonal content and potency of oral contraceptives and breast cancer risk among young women
Br J Cancer
(2003) - et al.
Oral contraceptives and myocardial infarction
Br J Fam Plann
(2003)
Cited by (59)
Progesterone – Friend or foe?
2020, Frontiers in NeuroendocrinologyCitation Excerpt :Second, the risk of mental health problems in observational studies is present in the POP users as well (Skovlund et al., 2016; Zettermark et al., 2018). Third, the type of progestogen seems to play a significant role for the surfacing of symptoms during CHC use, where anti-androgenic progestogens seem to be more advantageous than androgenic progestogens (Kelly et al., 2010; Sangthawan and Taneepanichskul, 2005; Bruni et al., 2000; Winkler et al., 2004). Additionally, knowing the lifetime prevalence of mood and anxiety disorders in women, it is presumable that HC-induced mental symptoms may be triggered by preexisting vulnerability.
Nonsteroidal antiinflammatory drug resistance in dysmenorrhea: epidemiology, causes, and treatment
2018, American Journal of Obstetrics and GynecologyCitation Excerpt :Nomegestrol acetate/17β-estradiol was more effective in treating menstrual pain when compared to drospirenone/ethinylestradiol oral contraceptive.84 A comparison of 20 μg ethinyl estradiol/150 μg desogestrel to 20 μg ethinyl estradiol/100 μg levonorgestrel suggested each improved dysmenorrhea similarly (23% and 26% of women, respectively).85 Combination OCPs with estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel both reduced experienced time of dysmenorrhea pain by 4 days, but significant differences between the regimens were not observed.86
A Review of hormone-based therapies to treat adult acne vulgaris in women
2017, International Journal of Women's DermatologyPreliminary evidence on the effect of Yoga on the reduction of edema in women with premenstrual syndrome
2017, European Journal of Integrative MedicineEffects of low-dose combined drospirenone–ethinylestradiol on perimenstrual symptoms experienced by women with endometriosis
2016, International Journal of Gynecology and ObstetricsCitation Excerpt :Generally, OCPs act by suppressing ovulation and prostaglandin synthesis, thereby reducing menstrual bleeding and relieving menstrual pain. OCPs can be administered for relatively long durations because they are safe and well tolerated with minimal severe adverse effects [4–7]. The 17α-spironolactone derivative drospirenone has anti-mineralocorticoid, anti-androgen, and progestational activity, and is less commonly associated with sodium and water retention than oral contraceptives, which cause adverse effects such as edema and weight gain [8].
Polycystic ovary syndrome: A review for dermatologists: Part II. Treatment
2014, Journal of the American Academy of Dermatology